{"filings":[{"id":115209,"accession_number":"0001493152-26-006785","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ProPhase Labs invites investors to webinar on Feb 3, 2026; details not available","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Issued press release on Feb 2, 2026 inviting investors to a webinar on Feb 3 at 4:15pm ET.","Webinar intended to provide insight into ProPhase's portfolio of high-growth healthcare assets.","Press release furnished as Exhibit 1.1 but not included in filing text; specific details unknown.","Confidence low due to absence of exhibit content in the provided filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115208,"accession_number":"0001493152-26-006784","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ProPhase Labs initiates sale process for BE-Smart esophageal cancer test; updates on COVID-19 receivable collections","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated potential sale or strategic partnership for BE-Smart, a CLIA/CAP-accredited LDT for esophageal cancer risk; outreach to >70 acquirers.","Crown Medical Collections: >60% of aggregate claims are from commercial payors that partially reimbursed, implying higher recovery rates.","Laboratory subsidiaries are in Chapter 11; legacy COVID-19 testing receivables being addressed via Crown Medical Collections initiative."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115207,"accession_number":"0001493152-26-003724","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ProPhase Labs provides update on Crown Medical Collections initiative for COVID-19 testing receivables","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Update covers legacy COVID-19 testing receivables held by lab subsidiaries currently in Chapter 11 proceedings.","Press release issued January 26, 2026; specific progress metrics not included in this filing.","Crown Medical Collections initiative is the focus of the operational update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115206,"accession_number":"0001493152-26-003460","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ProPhase Labs uplisted from Pink Sheets to OTCID Market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Common stock approved for OTCID Market listing effective January 22, 2026.","Previously traded on Pink Sheets; ticker symbol remains PRPH.","Company issued a press release on January 22, 2026, announcing the uplisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115205,"accession_number":"0001493152-26-003456","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ProPhase Labs secures $10M equity line facility with Generating Alpha Ltd","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stock Purchase Agreement with Generating Alpha Ltd provides up to $10M equity capital at Company's election.","Issued 549,105 common shares and a prefunded warrant for 240,369 shares at $0.00 as commitment fee.","Company retains full discretion over facility drawdowns; no obligation to access it.","Securities issued in reliance on Section 4(a)(2) and Regulation D exemptions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115204,"accession_number":"0001493152-26-001143","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ProPhase Labs updates on convertible debt conversions, reverse stock split, and transition to OTC market","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Over $3.3 million of convertible debt converted from $3.8 million principal, reducing indebtedness and increasing equity; remaining unconverted principal less than $500,000.","Reverse stock split of 1-for-10 effective December 5, 2025, and transition from Nasdaq to OTC market effective January 5, 2026.","Management states recent stock volatility due to short-term technical factors including debt conversions and delisting, not changes in underlying asset value.","Conversion floor price of $0.76 per share (post-split) is above current trading price, reducing potential for further conversion-driven selling pressure.","Company reiterates focus on stabilizing capital structure and advancing operations; no fundamental change in long-term strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115203,"accession_number":"0001493152-26-001134","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Warren Hirsch resigns from ProPhase Labs Board effective Jan 5, 2026.","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Warren Hirsch resigned from the Board of Directors on January 5, 2026, effective immediately.","Resignation not due to any disagreement with Company operations, policies, or practices.","Company expressed gratitude for Hirsch's service and contributions during his tenure.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115202,"accession_number":"0001493152-26-000175","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"ProPhase Labs receives Nasdaq delisting notice for bid-price non-compliance; trading to suspend Jan 5","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq staff determination on Dec 29, 2025: company failed to regain compliance with minimum $1.00 bid price rule after two 180-day periods ending Dec 22.","Common stock trading will be suspended at the open on Jan 5, 2026; Nasdaq will file Form 25 to remove the listing.","Company intends to timely request a hearing before Nasdaq Hearings Panel to appeal the staff determination.","Concurrently, ProPhase is applying for quotation of its common stock on the OTC Markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131628,"accession_number":"0001493152-25-028537","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ProPhase Labs signs non-binding LOI for reverse merger with ABL, ABL to become majority owner","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["ProPhase Labs (PRPH) entered a non-binding LOI for a reverse merger with Advanced Biological Laboratories S.A. (ABL), a European biotech firm.","Under the proposal, ABL would become the majority owner of the combined entity.","The LOI is non-binding; no definitive agreement or financial terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131627,"accession_number":"0001493152-25-028483","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["8.01","5.1","9.01"],"status":"ready","headline":"ProPhase Labs files replacement legal opinion; retains new counsel","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Replacement opinion of counsel filed under Item 9.01, superseding prior opinion from Oct 15, 2025.","New legal counsel retained; prior opinion rendered of no further effect.","No financial or operational impact disclosed; purely administrative filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131620,"accession_number":"0001493152-25-028317","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K/A","filed_at":"2025-12-18T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"ProPhase Labs files 1-for-10 reverse stock split effective Dec 22, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 1-for-10 reverse split on Nov 30, 2025; Certificate of Amendment filed with Delaware on Dec 2.","Reverse split effective 8:00 a.m. ET Dec 22, 2025; trading symbol remains PRPH under new CUSIP.","Post-split shares outstanding approximately 5,768,951; fractional shares rounded up to whole shares.","Purpose: to increase per-share trading price to meet Nasdaq continued listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131626,"accession_number":"0001493152-25-027317","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"ProPhase Labs effects 1-for-10 reverse stock split to meet Nasdaq listing requirements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-10 ratio effective December 2, 2025, approved by board and stockholders on November 30, 2025.","Post-split common shares outstanding approximately 5,768,951; trading symbol unchanged (PRPH).","Reverse stock split implemented to increase per-share price to meet continued Nasdaq listing requirements.","Fractional shares rounded up to nearest whole share; par value remains $0.0005 per share.","Certificate of Amendment filed with Delaware Secretary of State on December 2, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131619,"accession_number":"0001493152-25-027399","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K/A","filed_at":"2025-12-12T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"ProPhase Labs to effect 1-for-10 reverse stock split to maintain Nasdaq listing","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved reverse stock split on Nov 24, 2025; board approved Nov 30, 2025.","Certificate of Amendment filed Dec 2, 2025; split effective Dec 22, 2025 at 8:00 AM ET.","After split, approximately 5,768,951 shares of common stock will be outstanding.","No fractional shares; any fractional shares rounded up to whole share.","Reverse split intended to increase per-share price to meet Nasdaq continued listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131625,"accession_number":"0001493152-25-025102","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"ProPhase Labs shareholders approve digital-asset acquisitions, stock split authorization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 (digital asset acquisitions) approved: 15,250,528 for, 582,008 against.","Proposal 2 (digital treasury shares) approved: 15,194,678 for, 615,619 against.","Proposal 3 (digital token issuance) approved: 15,107,219 for, 618,878 against.","Proposal 4 (reverse/forward stock split) approved with 63.57% of outstanding shares (27,961,611 for).","Proposals 5 (increase authorized common stock) and 6 (adjournment) also approved with strong majorities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131624,"accession_number":"0001493152-25-024988","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ProPhase Labs discloses unsealed False Claims Act qui tam suit; government declined intervention","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Civil action unsealed Nov 4, 2025; company learned Nov 19-21, 2025, no prior knowledge of sealed 2023 filing.","U.S. and states declined intervention; company not served, denies wrongdoing, will defend vigorously.","Private disputes with relator Dr. Hennrick settled and dismissed with prejudice in April 2024.","Company states no material impact expected on operations or ability to continue services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131623,"accession_number":"0001493152-25-024986","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"ProPhase Labs receives Utah judgment on Avtech lease; forbearance extended with revised payment schedule","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Judgment entered on Nov 5, 2025 in Utah for Avtech equipment lease; company received it on Nov 19, 2025.","Avtech confirmed forbearance continues; weekly payments start Nov 28, 2025 until past-due amounts current, then resume original monthly schedule.","Company states judgment does not affect operations, liquidity, or financial reporting; no restatement required.","Most recent Form 10-Q reflected all required accruals; payments being made consistently under updated schedule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131622,"accession_number":"0001493152-25-024174","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ProPhase Q3 net loss $6.8M, revenue down 36%; working capital deficit $47.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss from continuing ops $6.8M ($0.16/sh) vs $5.0M ($0.26/sh) prior year; revenue $0.9M down from $1.4M","Cash $405K; working capital deficit $47.5M at Sep 30 vs $1.5M at Dec 31, 2024","Crown Medical appointed Special Counsel to recover $50M+ net A/R; first settlement completed","BE-Smart esophageal cancer test validated by Mayo Clinic; commercialization rollout underway","Nebula Genomics pro-forma profitable; strategic M&A discussions ongoing"],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":3561000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131621,"accession_number":"0001493152-25-018123","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ProPhase Labs enters into ATM equity offering facility with WestPark Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ProPhase Labs entered an At-the-Market Sales Agreement with WestPark Capital on Oct 9, 2025, to sell common stock from time to time.","Agent receives 3.0% commission on gross proceeds; company reimburses certain expenses.","Sales made under existing effective S-3 registration statement (No. 333-283182) declared effective Nov 20, 2024.","Company is not obligated to sell any shares; may suspend or terminate agreement at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148194,"accession_number":"0001493152-25-014057","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ProPhase Labs engages ThinkEquity for $6M private placement; crypto treasury strategy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive strategic advisory and placement agent agreement for proposed $6M private placement of securities on best efforts basis.","Compensation includes 8% cash fee, PA Warrants (8% of shares placed), and Advisory Warrants tied to crypto accumulation milestones.","ThinkEquity earns 1.25M warrants at close, 1.25M after $50M crypto, 1M after $100M crypto; warrants five-year term.","ThinkEquity may appoint one board member once company accumulates $50M in crypto."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148193,"accession_number":"0001493152-25-013415","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["1.01","5.02","5.03","5.07","9.01"],"status":"ready","headline":"ProPhase Labs shareholders approve share increase to 1B and equity plans","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved increase in authorized common shares from 50M to 1B at Sept 9 special meeting.","Approved amendments to 2022 equity plan and 2025 equity plan, enabling executive participation.","Warrants to CEO Ted Karkus and an investor for 500k shares each now fully exercisable.","Company can now reserve 400% of shares for conversion of July 2025 20% OID notes and warrants.","Bylaw amendment to update principal office address approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148192,"accession_number":"0001493152-25-012414","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"ProPhase Labs terminates $7.7M equity line with Keystone Capital Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Common Stock Purchase Agreement with Keystone Capital Partners effective August 28, 2025.","Agreement allowed sale of up to ~$7.7M of common stock at Company’s option.","Termination was at sole discretion, with no penalties or termination fees.","No other material relationships between Company and Keystone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148191,"accession_number":"0001641172-25-024730","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ProPhase Labs adjourns special meeting to Sept 9; proposes 1B authorized shares and crypto treasury strategy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Definitive proxy filed Aug 15; SEC completed review with no further comments on Aug 18.","Special meeting adjourned from Aug 29 to Sept 9, 2025 at 273 Merrick Rd, Lynbrook, NY.","Proposals include increasing authorized shares from 50M to 1B, $15M share repurchase, and expanded equity compensation.","Board recommends voting FOR proposals to support crypto treasury strategy and growth of BE-Smart test and Nebula Genomics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148190,"accession_number":"0001641172-25-023344","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ProPhase Labs Q2 net loss narrows to $4.5M, gross margin turns positive; patent for BE-Smart; crypto treasury approved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $1.2M vs $1.5M YoY; net loss from continuing ops $4.5M ($0.11/share) vs $5.5M ($0.29/share).","Gross margin improved to 58.9% from (10.3)% YoY; operating expenses cut 35% YTD; sale of PMI generated $8.7M gain.","U.S. patent granted for BE-Smart esophageal adenocarcinoma test in August 2025; accelerates commercialization.","Board approved crypto treasury strategy including Bitcoin; proposed authorized share increase to 1 billion for flexibility.","Stockholders' equity rose to $11.5M (from $7.4M at year-end); cash $169K; Crown Medical estimates $50M recovery."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":2678000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148189,"accession_number":"0001641172-25-022426","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ProPhase Labs COO resigns, appoints fractional CFO Steven Plumb","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Stu Hollenshead resigned July 31, 2025, not due to any disagreement; will serve as marketing consultant.","Company will search for new COO; duties shared among executive management team in interim.","Appointed Steven M. Plumb as fractional CFO effective Aug 6, 2025, via Clear Financial Solutions.","Plumb to provide 25 hours/month at $10,000/month on month-to-month basis; CEO Ted Karkus remains principal financial officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148188,"accession_number":"0001641172-25-021262","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ProPhase Labs to seek shareholder approval to increase authorized shares to 1 billion for crypto treasury strategy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting of Shareholders on August 29, 2025 to vote on increasing authorized shares to 1 billion.","Board unanimously recommends approval to attract high-value crypto treasury transactions and market participants.","Company aims to collect approximately $50 million from COVID accounts receivables to fund potential crypto strategy.","Continuing development of BE-Smart esophageal cancer test and exploring strategic alternatives for Nebula Genomics, including a possible sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148187,"accession_number":"0001641172-25-021109","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"ProPhase Labs raises $2.75M via senior secured convertible notes with 20% OID and warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Notes have $3.75M face value after 20% OID; net proceeds ~$2.75M; mature July 22, 2026.","Notes bear 10% interest; convertible after 4 months at lower of 80% of trailing 10-day VWAP or fixed max with floor/caps.","Warrants to purchase up to 5.25M shares at $0.50/share for 5 years; reserve may increase to 226M shares after shareholder vote.","CEO and another investor subordinated prior $1M secured loans; security interest covers substantially all assets (excl. certain subsidiaries).","Special meeting of stockholders set for Aug 29, 2025 to vote on authorizing additional shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148186,"accession_number":"0001641172-25-020898","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"ProPhase Labs regains Nasdaq compliance after annual meeting; all director nominees elected","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["All four director nominees (Karkus, Gleckel, Hirsch, Abenante) elected; say-on-pay approved with 85.3% support.","Stockholders selected 3-year frequency for say-on-pay; board adopts, next vote in 2028.","Newly elected Abenante appointed to Audit Committee, making it three independent directors, regaining Nasdaq compliance.","Company notified Nasdaq it has regained compliance with Rule 5605(c)(2)(A)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148185,"accession_number":"0001641172-25-020651","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ProPhase Labs closes $3M senior secured convertible notes with warrants at $0.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Notes have 20% original issue discount, secured by Company assets, not convertible for first 4 months.","Investors also receive warrants exercisable at $0.50 per share; up to $3M additional notes available.","Proceeds for working capital, general corporate purposes, and repayment of certain existing debt.","CEO cites potential near-term liquidity events: up to $50M COVID AR collection and possible Nebula Genomics sale.","Company exploring reverse merger crypto treasury strategy leveraging Nebula's blockchain expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148184,"accession_number":"0001641172-25-020357","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ProPhase Labs board authorizes exploring reverse merger with crypto-focused company and Bitcoin treasury","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board unanimously authorized exploring reverse merger with a digital asset-focused operating company (crypto treasury management).","Board approved strategic treasury initiative to acquire and hold digital assets, including Bitcoin, for long-term value.","No binding agreement yet; management will conduct diligence and evaluate shareholder interests.","CEO cites goal to preserve existing asset value: Crown Medical Collections (up to $50M net), Nebula Genomics, BE-Smart test.","Company is a biotech/genomics/consumer products firm considering a pivot into digital assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148183,"accession_number":"0001641172-25-017286","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"ProPhase Labs regains Nasdaq compliance after appointing new independent director","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Appointed Carolina Abenante as independent director on June 20, 2025.","Abenante will join the Audit Committee effective July 19, 2025, the day after the annual meeting.","Nasdaq confirmed compliance with Listing Rule 5605(c)(2) on June 25, 2025, closing the matter.","Non-compliance stemmed from Eleanor McBrier's resignation in September 2024, causing an audit committee vacancy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166950,"accession_number":"0001641172-25-016815","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K/A","filed_at":"2025-06-27T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"ProPhase Labs enters $1M bridge loan (20% OID) from CEO and investor; issues warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Each loan (CEO and investor) $500k principal, 20% OID ($625k face), 10% interest, 12-month maturity.","Company issued 500,000 unvested warrants per loan (1M total) at $0.60/share, vesting conditional on shareholder approval.","Loans secured but subordinate to up to $6M senior debt; proceeds for working capital; repayment via Nebula Genomics sale or Crown Medical collections.","CEO loan is related-party transaction; Audit Committee approved; Karkus receives $10,000 expense reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166954,"accession_number":"0001641172-25-016710","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"ProPhase Labs borrows $500K each from CEO and investor; issues 500K unvested warrants at $0.60","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $500,000 each from CEO Ted Karkus and an unaffiliated investor (total $1M) under two identical loan agreements.","Each loan has 20% original issue discount, 10% annual interest, 12-month maturity; secured but subordinated to up to $6M other lenders.","Issued 500,000 unvested warrants at $0.60 exercise price; vest only upon shareholder approval to increase authorized shares.","CEO loan is a related-party transaction approved by the Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166953,"accession_number":"0001641172-25-016692","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"ProPhase Labs receives 180-day Nasdaq extension to meet $1 bid price by Dec 22, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received additional 180-day extension from Nasdaq to comply with $1 minimum bid price requirement.","Initial compliance period ended June 24, 2025; company had not regained compliance.","Must have closing bid price ≥ $1.00 for 10 consecutive business days before December 22, 2025.","Failure to regain compliance by deadline will result in Nasdaq delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166952,"accession_number":"0001641172-25-016501","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ProPhase Labs appoints Carolina Abenante as independent director effective June 20, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ms. Abenante will serve on Nominating and Corporate Governance Committee and as Chair of Compensation Committee.","Her term expires July 18, 2025, at the annual meeting; she is nominated for election to a full term.","She will be appointed to the Audit Committee effective July 19, 2025, subject to independence and financial literacy.","Ms. Abenante is founder of NYIAX and holds multiple law degrees; she receives $48,000 annual retainer and equity participation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166951,"accession_number":"0001641172-25-011607","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ProPhase Q1 net loss narrows to $4.7M, cuts costs, eyes Nebula sale, $50M recovery","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenue $1.4M (down from $2.4M YoY); net loss $4.7M ($0.13/shr) vs $5.5M loss ($0.32/shr) last year.","Headcount slashed from 96 to 25; Pharmaloz divested for ~$23M, genomics lab closed, saving >$6M annually.","Engaged ThinkEquity to sell Nebula Genomics; 16-petabyte DNA dataset; sale expected within 3-4 months.","Crown Medical expects ~$50M in insurance recoveries; company carries $20M A/R for this initiative.","BE-Smart esophageal test submitted for peer review; LDT rule vacated by federal judge on Apr 1, 2025."],"consensus_eps_estimate":-1.836,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":1431000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184347,"accession_number":"0001641172-25-001488","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ProPhase Labs reports FY2024 net loss of $53.4M; revenue down 81% to $6.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue fell 80.6% to $6.8M from $35.0M, driven by near-zero COVID-19 testing volumes.","Net loss widened to $53.4M ($2.61/share) vs $16.8M ($0.98/share) in FY2023; gross loss of $0.2M.","Manufacturing division sold for ~$23M in Jan 2025; employee count reduced from 96 to 28.","Cash and equivalents $0.7M at Dec 31, 2024, down from $1.6M; working capital deficit of $1.5M.","Company plans cash-pay launch of BE-Smart esophageal test; evaluating sale of Nebula Genomics."],"consensus_eps_estimate":-1.836,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":1431000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184346,"accession_number":"0001493152-25-007880","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"ProPhase Labs appoints former Barstool Sports COO Stu Hollenshead as new COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stuart Hollenshead appointed COO effective Feb 17, 2025, replacing Jed Latkin who resigned Feb 14.","Hollenshead receives $190k base salary and stock options for 500k shares at $0.60 strike, vesting over 3 years.","Company signals potential significant accounts receivable inflow and strategic alternatives for Nebula/DNA Complete.","Hollenshead will continue as CEO of 10PM Curfew, a female media platform reaching 70M women.","CEO cites Hollenshead's role scaling Barstool Sports (sold for $551M) and expertise in DTC growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184345,"accession_number":"0001493152-25-006473","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ProPhase Labs COO Jed Latkin departing Feb 14; Stuart Hollenshead in talks to replace him","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jed Latkin, COO, leaves Feb 14, 2025, to pursue other opportunities; will consult on projects.","Latkin gets $100K performance bonus for Q1 2025, including for Pharmaloz Manufacturing sale work.","Company in final stages to appoint Stuart Hollenshead as new COO.","Hollenshead currently CEO of 10PM Curfew; ex-COO/CBO of Barstool Sports.","Departure is not related to any disagreement with company operations or policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184344,"accession_number":"0001493152-25-004210","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ProPhase Labs enters $7.73M equity line with Keystone Capital; issues 352,176 commitment shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $7,730,973 of common stock may be sold to Keystone Capital at 90% of lowest traded price or VWAP.","Commitment fee: 352,176 shares issued to investor as consideration for the purchase commitment.","Use of proceeds: working capital and general corporate purposes; 30% to redeem preferred stock if issued.","Each fixed purchase limited to lower of 100,000 shares or $100,000; VWAP purchases capped at $5M aggregate.","Investor prohibited from short sales or hedging during term; company retains termination right upon one day notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184343,"accession_number":"0001493152-25-003425","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"ProPhase Labs sells Pharmaloz subsidiaries for $2M cash and $10M debt relief","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["JL Projects purchased all shares of Pharmaloz Manufacturing and Pharmaloz Real Estate; transaction closed Jan 16, 2025.","JL Projects provided $2M cash and extinguished $10M of ProPhase's debt; also cancelled $300K accrued interest.","JL Projects assumed $3.3M mortgage, $2M capital leases, and $3M payables; paid down $200K affiliate loan.","ProPhase avoided $3M in upcoming capex and transferred $600K employee overhead to PMI.","Sale includes customary representations and warranties; full agreement filed as Exhibit 2.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200938,"accession_number":"0001493152-24-052297","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2024-12-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"ProPhase Labs receives Nasdaq bid price deficiency notice; 180-day cure period until June 24, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Dec 26, 2024 for bid price below $1.00 for 30 consecutive business days.","Has until June 24, 2025 to regain compliance by closing at $1.00+ for 10 consecutive business days.","Company qualifies for potential second 180-day extension due to stockholders' equity >= $5M.","Failure to regain compliance may lead to delisting from Nasdaq.","Management states they are working to evidence compliance, but no assurance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200937,"accession_number":"0001493152-24-045123","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ProPhase Labs Q3 net revenue $3.1M (down 63% YoY); net loss $6.6M ($0.35/sh)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $3.1M vs $8.4M in Q3 2023; net loss $6.6M ($0.35/sh) vs $5.1M ($0.30/sh).","Pharmaloz Manufacturing hired ThinkEquity to explore sale; projects $15M+ revenue over next 12 months.","BE-Smart esophageal cancer test initiated partnership talks with two billion-dollar diagnostic firms.","Equivir trial completed; final stats expected by end-November; preliminary data encouraging.","Cash $1.1M at Sep 30; plans to eliminate ~$6M/year overhead; working capital $13.5M."],"consensus_eps_estimate":0.408,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":9254000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200936,"accession_number":"0001493152-24-044891","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"ProPhase Labs closes public offering of 4.8M shares at $0.72, raising ~$3.45M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 4,795,500 shares at $0.72 per share; gross proceeds $3.45M, net proceeds ~$3M.","Underwriters' over-allotment option fully exercised; ThinkEquity acted as sole book-runner.","Net proceeds to be used for working capital, general corporate purposes, and potential acquisitions.","Directors/executives subject to 120-day lock-up; 5%+ holders subject to 90-day lock-up.","Representative warrants issued to purchase up to 5% of shares at $0.90 per share, exercisable after 180 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200935,"accession_number":"0001493152-24-044017","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ProPhase Labs proposes public stock offering; discloses $500K term note and future receipts deals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Announced underwritten public offering of common stock and/or pre-funded warrants; no size or price disclosed.","ThinkEquity sole book-running manager; proceeds earmarked for working capital, product development, and M&A.","Disclosed $500K term note at 15% interest and two future receipts financings aggregating ~$2.1M.","BE-Smart esophageal cancer test faces regulatory uncertainty due to new FDA LDT rule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200934,"accession_number":"0001493152-24-041600","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"ProPhase Labs engages Fruci & Associates as new auditor after Morison Cogen resignation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Morison Cogen LLP resigned as independent auditor effective September 30, 2024.","Fruci & Associates II, PLLC engaged as new auditor for fiscal year ending December 31, 2024.","No consultations on accounting or auditing issues occurred with the new accountant prior to engagement.","No disagreements or reportable events with former auditor during the past two fiscal years.","Auditor change approved by the board of directors on October 18, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200933,"accession_number":"0001493152-24-039578","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"ProPhase Labs auditor Morison Cogen resigns due to exit from PCAOB audit business","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Morison Cogen resigned as independent auditor effective September 30, 2024, because it decided to exit the PCAOB audit market.","No disagreements with Morison on accounting principles, financial disclosure, or audit scope during 2022, 2023, and through resignation.","Prior adverse opinion on internal control over financial reporting in 2023 10-K and material weaknesses disclosed in 2024 quarterly reports.","Company expects to announce engagement of a new independent registered public accounting firm in the near future."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216956,"accession_number":"0001493152-24-038339","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"ProPhase Labs director Eleanor McBrier resigns; Nasdaq audit committee vacancy triggers non-compliance cure period","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eleanor McBrier resigned as director effective Sep 20, 2024 due to conflict with employer policies; no dispute with company.","Vacancy on audit committee caused non-compliance with Nasdaq Listing Rule 5605(c)(2)(A).","Nasdaq confirmed non-compliance on Sep 26; cure period ends earlier of next annual meeting or Sep 20, 2025.","Company plans to regain compliance and is searching for a replacement with gastroenterology focus for BE-Smart test."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216953,"accession_number":"0001493152-24-033487","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K/A","filed_at":"2024-08-22T23:59:59+00:00","items":["8.01","1.01","2.03","9.01"],"status":"ready","headline":"ProPhase Labs issues $10M amended promissory note at 15% interest, due 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended and restated unsecured promissory note to JXVII Trust for $10M principal, replacing $7.6M note from Jan 2023.","Note bears 15% annual interest, payable quarterly, maturing August 15, 2027; prepayable without penalty.","As of June 30, 2024, working capital $16.1M, cash $2.4M, outstanding debt $13.6M net of discounts.","Proceeds used for working capital, product development, and potential acquisitions.","Risk factor added highlights potential inability to service debt and need for additional capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216955,"accession_number":"0001493152-24-033465","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"ProPhase increases debt to $10M at 15% interest; adds risk factor on debt service","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended note principal increased from $7.6M to $10.0M; additional net cash of ~$2.31M after interest.","Note matures Aug 15, 2027, with 15% annual interest, quarterly payments; prepayable without penalty.","As of June 30, 2024, company had $13.6M total debt (net of discounts) and only $2.4M cash.","Proceeds for working capital, capex, product development, and M&A.","New risk factor warns cash flow may not be sufficient to service debt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216954,"accession_number":"0001493152-24-031881","cik":868278,"company_name":"ProPhase Labs, Inc.","ticker":"PRPH","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ProPhase Labs Q2 revenue falls 81% to $2.5M; net loss $(0.33) per share; eyes H2 growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $2.5M vs $13.2M YoY; net loss $6.2M ($0.33 per share) vs $3.4M ($0.20) in Q2 2023.","COVID-19 testing revenue zero (126K tests in prior year); overall gross margin negative 19.2%.","Pharmaloz projects $14-16M revenue and >$5M pre-tax profit over next 12 months; exploring potential sale.","Nebula Genomics launching revamped DTC product 'DNA Complete' with influencer marketing campaign.","Cash and equivalents $2.4M; working capital $16.1M; expects significant sequential revenue growth in Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":6108000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":949329.0548424739,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-08-14T23:59:59+00:00|216954"}